Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Current Deferred Revenue (2022 - 2024)

Werewolf Therapeutics (HOWL) has disclosed Current Deferred Revenue for 3 consecutive years, with $502000.0 as the latest value for Q1 2024.

  • Quarterly Current Deferred Revenue changed N/A to $502000.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $502000.0 through Mar 2024, changed N/A year-over-year, with the annual reading at $1.3 million for FY2023, 82.51% down from the prior year.
  • Current Deferred Revenue for Q1 2024 was $502000.0 at Werewolf Therapeutics, down from $1.3 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $7.7 million in Q4 2022, with the low at $502000.0 in Q1 2024.
  • Average Current Deferred Revenue over 3 years is $2.9 million, with a median of $2.4 million recorded in 2023.
  • Peak annual rise in Current Deferred Revenue hit 82.51% in 2023, while the deepest fall reached 82.51% in 2023.
  • Over 3 years, Current Deferred Revenue stood at $7.7 million in 2022, then crashed by 82.51% to $1.3 million in 2023, then tumbled by 62.54% to $502000.0 in 2024.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $502000.0, $1.3 million, and $2.4 million for Q1 2024, Q4 2023, and Q3 2023 respectively.